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Introduction
Hypospadias (where the urethral opening develops on the ventral aspect of the penis, scrotum or perineum) and undescended testis (UDT; the absence of one or both testes from the scrotum) are the most common genital anomalies in males (Paulozzi, 1999) . Both anomalies require surgical repair during childhood and have been associated with long-term adverse functional, cosmetic and fertility outcomes (Lee and Coughlin, 2001) ; and with increased risk of malignancy in adulthood (Schnack, et al., 2010) .
The development of the male genital tract is highly dependent on testosterone production by Leydig cells and the function of their receptors (Blaschko, et al., 2012) . The placental hormone human chorionic gonadotropin (hCG), which peaks in production during early gestation, is secreted into both the maternal and foetal circulations, and has important roles in both pregnancy maintenance and testosterone production in the foetal testis (Molsberry, et al., 1982 , Scott, et al., 2009 . The peak in production during early gestation is critical for the normal fusion of the urethral fold. Thus, alteration in foetal hCG concentrations in early pregnancy might disrupt foetal testosterone production and result in abnormal gonadal development. Animal studies suggest that androgen blockage with flutamide occurring during the masculinization programming window between 8-14 weeks gestation results in the development of hypospadias and UDT (Welsh, et al., 2008) . Human studies have also reported an association between prenatal exposures to endocrine disruptive chemicals and male genital anomalies (Kalfa, et al., 2015 , Koskenniemi, et al., 2015 . hCG is also presumed to play a key role in optimal placental function with studies suggesting altered release in pregnancies affected by adverse outcomes such as preeclampsia and fetal growth restriction (Krantz, et al., 2004 , Norris, et al., 2011 . Adverse pregnancy outcomes have also been associated with hypospadias and UDT, implicating a possible role of an altered release of hCG to the developing fetus (Aschim, et al., 2004 , Biggs, et al., 2002 , Fujimoto, et al., 2008 .
Limited studies have assessed the association between maternal levels of hCG in early pregnancy with subsequent development of hypospadias and/or UDT, although results have been inconclusive. This in in part due to small numbers (Bernstein, et al., 1988 , Burton, et al., 1987 , Chedane, et al., 2014 , Kiely, et al., 1995 and heterogeneous clinical settings including different pathophysiological pathways and 6 phenotype severity such as the presence of other congenital anomalies (Brouwers, et al., 2010) or adverse pregnancy outcomes, indicative of poor placental development or function (Krantz, et al., 2004 , Norris, et al., 2011 .
The aim of the study was to investigate the association between maternal first trimester levels of serum hCG with hypospadias and UDT, and assess whether hCG levels are associated with specific phenotypes.
Materials and Methods

Ethics approval
Ethics approval for access and linkage of data was obtained from the NSW Population and Health
Services Research Ethics Committee and the Department of Health WA Human Research Ethics
Committee.
Study population and laboratory information
We conducted a record-linkage study of two separate populations of women attending first trimester screening in two Australian states, New South Wales (NSW) and Western Australia (WA), between July 2006 and December 2009; and between August 2001 and October 2003, respectively. Included were women who gave birth to a singleton live-born male infant. Information on free-beta hCG levels was collected as part of the Down syndrome serum screening test and were ascertained from the Pacific Laboratory Medicine Services (PaLMS) database in NSW and from laboratory databases accredited by the Fetal Medicine Foundation in WA. An Immulite 2000 assay system (Siemens Healthcare Diagnostics, Deerfield, IL, USA) was employed to measure free-beta hCG levels and the intra and inter assay variability was 6-8% and 8-10%, respectively. Laboratory data included free-beta hCG expressed as multiple of the medians (MoM) which accounts for differences in free-beta hCG by 7 gestational week at testing and maternal weight (Wald, et al., 1992) . Gestational week at the time of hCG testing was recorded in laboratory data and assessed by ultrasound using the crown-rump length.
Health data sources
Maternal information, pregnancy and male infant outcomes in NSW were obtained via record linkage of information from the PaLMS laboratory database to the NSW Perinatal Data Collection (PDC) and Admitted Patient Data Collection (APDC). The PDC is a statutory surveillance system of all live births and stillbirths in NSW of at least 20 weeks gestation or 400 g birth weight. It includes information on maternal demographic information, pregnancy conditions, birth factors, and infant outcomes. The 
Study outcomes and explanatory variables
Study outcomes were defined as any male infant with a recorded diagnosis of hypospadias or UDT requiring corrective surgery; and identified from relevant infant hospital admissions in NSW and 8 WARDA records in WA. Boys without a relevant recorded diagnosis were considered as the unaffected comparison group. Hypospadias cases were identified from the APDC using the ICD-10-AM code Q54 and from WARDA using the BPA-ICD9 code 7526. Cases were categorized by severity according to the classification by Duckett,1996 (Duckett, 1996 Unspecified: other (Q54.8) or unspecified hypospadias (Q54.9, 7526.0, 7526.6 and 7526.9). For those boys with more than one recorded hypospadias diagnosis, the most severe was used. Boys with UDT were identified from the APDC if they had a relevant ICD-10-AM code Q53 and underwent corrective surgery; either an orchidopexy (ACHI codes 37803, 37804, 37806 and 37812) or an orchidectomy (30641). Boys with UDT were identified from WARDA using the BPA-ICD9 code 7525. Only those UDT cases requiring corrective surgery are notified and recorded in the WARDA. All UDT cases were categorized by phenotypical type characterized by severity into unilateral or bilateral UDT according to the relevant diagnosis codes. Boys diagnosed with co-existing anomalies, excluding minor anomalies such as tongue-tie, naevus, skin tags, unstable hip and feet defects, were also differentiated from isolated cases. We excluded 16 boys from NSW and 13 from WA with recorded diagnosis of chromosomal anomalies as these are more likely to have abnormal levels of hCG.
The key explanatory variable for this study was first trimester free-beta hCG serum levels expressed as multiples of the median (MoM) of the total population of women attending first trimester screening in each state. Due to non-normality of free-beta hCG MoM distribution, these were expressed as medians and also categorized by quartile cut points at the 25 th , 50 th and 75 th centiles. Covariates included in the analysis were maternal age, weight (kilograms) ascertained at the time of first trimester screening, parity (nulliparae or multiparae), smoking during pregnancy and adverse pregnancy outcomes considered as potential markers of placental dysfunction (Odibo, et al., 2014 , Vinnars, et al., 2014 . A 9 composite variable of markers of placental dysfunction was developed comprising the occurrence of preterm birth (<37 weeks gestation), small for gestational age (SGA) defined as birth weight <10 th percentile of the nationwide distribution of birth weight by gestational age and infant sex (Dobbins, et al., 2012) or preeclampsia. Gestational age at birth was reported in the PDC data in completed weeks of gestation and determined by the best clinical estimate, including early ultrasound (97%) and last menstrual period. Preeclampsia was determined either by the relevant box being checked in the PDC or MNS record, or if any maternal APDC record had a diagnosis of preeclampsia (ICD-10-AM: O11 and O14) or eclampsia (O15). As maternal weight was missing in 1,736 (14.3%) and 998 (9.5%) of the NSW and WA records, respectively, multiple imputation was applied to predict missing values using existing values from other variables (Schafer and Olsen, 1998) . There were 5 (0.5%) women from WA with missing hCG information and these were excluded from the analysis.
Statistical analysis
Overall median and interquartile range (IQR) for 25 th and 75 th percentile cut points of free-beta hCG MoM levels by maternal characteristics and infant study outcomes were examined and differences assessed using the Kruskal-Wallis test. The characteristics of boys with hypospadias and UDT were compared with unaffected boys using Chi-squared test. Wilcoxon rank sum test was used to assess the median difference in maternal serum levels of free-beta hCG MoM between boys with hypospadias or UDT and unaffected boys. Differences in free-beta hCG MoM levels by phenotypical types of hypospadias and UDT, isolated versus co-existing congenital anomalies and women with suspected placental dysfunction versus those without were also assessed. Multivariable logistic regression analysis was performed to examine the association between low (<25 th centile) and high (>75 th centile) serum levels of free-beta hCG MoM with hypospadias and UDT, with the reference being levels between the 25 th and 75 th centiles. Potential confounder variables were only retained in the models if they were significant at p<0.05 and changed the association estimates by 10% or more. Secondary analyses were 10 also conducted by restricting to severe phenotypes of proximal hypospadias or bilateral UDT, those with co-existing congenital anomalies or women with suspected placental dysfunction. Where relevant, pooled odds ratio and corresponding 95% confidence intervals were calculated to combine results from NSW and WA. P-value <0.05 was considered statistically significant and all analyses were performed using SAS, 9.4 (SAS Institute, Cary, NC, USA).
Results
Population characteristics
A total of 12,099 and 10,518 boys in NSW and WA, respectively, whose mother underwent first trimester screening and with recorded serum free-beta hCG levels were included. The majority of samples were collected between 10 and 13 weeks gestation (NSW, n=10,484, 87%; WA, n=10,465, 99.5%).
There were 90 (0.7%) and 77 (0.7%) male infants with a recorded diagnosis of hypospadias; while 107 (0.9%) and 109 (1.0%) had UDT in NSW and WA, respectively. Of those with hypospadias, 42 (46.7%), 18 (20%), 6 (6.7%) and 24 (26.7%) in NSW and 43 (55.8%), 27 (35.1%), 3 (3.9%) and 4 (5.2%) in WA had recorded diagnosis of anterior, middle, proximal and unspecified hypospadias, respectively. There were 97 boys (90.7%) in NSW and 102 (93.6%) in WA with a recorded diagnosis of unilateral; and 10 boys (9.3%) and 7 (6.4%) with bilateral UDT, respectively. Table I compares the maternal characteristics and infant outcomes for cases and unaffected boys. There was no overall difference in maternal age and smoking between cases and unaffected boys in either NSW or WA, although, higher maternal weight and multiparity was associated with increased rates of UDT in NSW but not in WA. Boys with hypospadias and UDT were more likely to be born to mothers with suspected placental dysfunction and to have coexisting congenital anomalies in both populations (Table I) .
Maternal free-beta hCG and genital anomalies
Table II presents maternal free-beta hCG levels by maternal characteristics and by phenotypical type of hypospadias and UDT. Median (IQR) levels of free-beta hCG MoM in NSW and WA decreased with increasing maternal weight; and differed by parity and smoking status, while levels were not affected by maternal age in either population. The association between free-beta hCG levels with hypospadias and UDT is presented in Table III for NSW and Table IV for WA. There were no differences in median freebeta hCG MoM for mothers with boys with recoded diagnosis of hypospadias or UDT versus unaffected boys. Results did not change restricting analyses to those with co-existing congenital anomalies or suspected placental dysfunction and there was no association between low (<25 th centile) or high (>75 th centile) maternal serum free-beta hCG MoM levels for these factors and hypospadias or UDT.
When comparing results for women having boys with milder hypospadias types in NSW (n=84; Similar results were obtained comparing unilateral with bilateral UDT (NSW: n=10; median 1.17 MoM; IQR: 0.71-1.75; p=0.43; WA: n=7; median 1.18, IQR: 0.33-1.79; p=0.77). Compared with milder types of hypospadias and unilateral UDT, high free-beta hCG MoM (>75 th centile) was associated with proximal hypospadias (NSW: odds ratio (OR) 3.38; 95%CI: 0.52-21.8; WA: OR 7.25; 95%CI: 0.62-85.2) and bilateral UDT (NSW: OR 2.41; 95%CI: 0.55-10.5; WA: OR 2.31; 95%CI: 0.48-11.0). An analysis pooling results for NSW and WA revealed that mothers giving birth to boys with severe types of hypospadias or bilateral UDT were more likely to have higher levels of free-beta hCG MoM in early pregnancy (proximal hypospadias: OR 4.34; 95%CI: 1.08-17.4 and bilateral UDT: OR 2.86; 95%CI:
1.02-8.03). Although numbers of cases were small, confidence intervals excluded unity.
Discussion
This is one of the largest population-based studies examining the association between maternal first trimester serum levels of free-beta hCG and genital anomalies, hypospadias and UDT. Overall, we found that maternal levels of free-beta hCG were not associated with subsequent development of hypospadias or UDT among male infants. However, levels of free-beta hCG tended to be higher among women who had boys with more the severe phenotypical types of proximal hypospadias or bilateral UDT.
There have been four previous studies examining the association between maternal levels of freebeta hCG and hypospadias or UDT and findings are summarized in Table V . Our results are consistent with three studies that reported no difference in first trimester maternal levels of free-beta hCG with hypospadias or UDT, compared to controls (Bernstein, et al., 1988 , Burton, et al., 1987 , Kiely, et al., 1995 . In contrast, a recent study found lower levels of free-beta hCG MoM in women who had a boy with UDT (Chedane, et al., 2014) , however, the differences reported were small. First trimester maternal levels of free-beta hCG are currently used for screening to detect Down syndrome fetuses and the reported differences in free-beta hCG levels between Down syndrome and controls are considerably larger (cases: median free-beta hCG MoM 1.70 versus controls: median 1.01; P < 0.0001) (Koster, et al., 2011) . Differences in hCG MoM levels were not evident in our overall findings for hypospadias and UDT. Our results suggest that the majority of these genital anomalies develop in the setting of normal maternal serum hCG levels. Perhaps these cases are associated with altered expression of the androgen receptor in gonadal fetal tissue (Drabik, et al., 2015) or altered secretion or metabolism of foetal hCG that is not reflected by maternal hCG levels.
To our knowledge this is the first study comparing maternal levels of free-beta hCG in specific phenotypical types of hypospadias or UDT. We did find that for boys with severe types, their mothers had higher levels of free-beta hCG but due to small sample size, our results were imprecise. In a previous study including women with severe placental dysfunction and intrauterine growth restriction (n=30), 62% had boys with proximal hypospadias, and authors reported a high mean hCG of 2.5 MoM (Yinon, et al., 13 2010) . Although the study did not include a comparative control group, their mean levels are consistent with levels of hCG above the 95 th percentile reported in population-based studies (Krantz, et al., 2004) .
These results suggests that severe hypospadias phenotypes may have different underlying aetiology involving higher production and secretion of hCG, similar to that which occurs in Down syndrome pregnancies (Eldar-Geva, et al., 1995) . Additionally, high gonadotropins may be associated with bilateral UDT due to deficient androgenic negative feedback, representing an affected hypothalamic-pituitary axis (Thorup, et al., 2012) or disrupted hCG receptors in the fetal testis (Lei, et al., 2001) . Limited androgen stimulation may also be a possible factor for the nearly three quarters of severe idiopathic hypospadias cases occurring in the absence of genetic alterations (Boehmer, et al., 2001) . However, we had no information in our data to suggest a reduced fetal testosterone secretion in proximal hypospadias or bilateral UDT, nor of the ability of fetal testosterone to inhibit placental hCG secretion. Indeed, placental aromatase might be expected to inactivate fetal testosterone as it enters trophoblast cells (Pasqualini, 2005) . Further research is needed to explore the consistency of these findings and potential diagnostic accuracy of maternal hCG in detecting proximal hypospadias or bilateral UDT.
The main strength of this study was the use of large record-linked population-based cohorts of women and boys across NSW and WA. The health datasets used are accurate and reliable with high agreement with medical records (Lain, et al., 2012) . Furthermore, our rates of hypospadias and UDT were similar and consistent with population estimates in NSW and WA (Nassar, et al., 2007 , Schneuer, et al., 2015 . One limitation of the study was the small numbers of proximal hypospadias and bilateral UDT in both cohorts. Although we conducted pooled analyses, results reported on these should be interpreted with caution. Another limitation was that since we assessed gestational age by ultrasound, the hCG concentrations from mothers with fetuses who were small or large for gestational age may have been inaccurately adjusted in MoM calculations. Despite the reliability of our datasets in identifying adverse pregnancy outcomes, we did not have pathology information to confirm tissue lesions in the placenta and therefore our composite outcome should be considered as a proxy for placental dysfunction. Moreover, 14 we could not differentiate between congenital and acquired UDT cases due to poor reporting of UDT at birth in our data. Congenital and acquired UDT may also have different etiology, although, the proportion of acquired cases in both study cohorts is likely to be low due to limited follow-up information.
Conclusions
First trimester maternal serum levels of free-beta hCG are not associated with subsequent development of hypospadias or UDT. However, high maternal levels of free-beta hCG were found in more severe types of male genital anomalies and suggest an altered pathway of hormonal metabolism in early pregnancy. These findings require further exploration and replication.
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